Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Recruiting

• Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Hodgkin
• Interventions: Drug: Chemotherapy

• Registration Number: NCT03117036
• Lead Sponsor: Samsung Medical Center

Brief Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Detailed Description

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows.

1. Registration after informed consent.

2. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood

3. Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood

4. Regular monitoring disease status and update of survival status

5. Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2017-03-01
• Study First Submitted: 2017-04-12
• Study First Submitted QC: 2017-04-12
• Study First Posted: 2017-04-17
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-27
• Last Update Posted: 2024-12-02
• Primary Completion: 2024-12-28
• Study Completion: 2026-12-28

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
2. 20 years
3. Patients requiring systemic chemotherapy with curative intent
4. Written informed consent

Read More

Exclusion Criteria

1. Myeloid malignancy
2. Multiple myeloma
3. Patients do not require systemic chemotherapy with curative intent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Lymphoma	Chemotherapy	Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.

Primary Outcome Measures

Name	Time	Method
Response rate	3 months after chemotherapy	response to chemotherapy

Secondary Outcome Measures

Name	Time	Method
Biomarker	3 year	Development of biomarker predicting response and survival outcome
Progression-free survival	3 year	Time to relapse/progression or any kinds of death
Overall survival	3 year	Time to any kinds of death

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of